Reference: Tareq, A. M., Bin Emran, T., Dhama, K., Dhawan, M., & Tallei, T. E. (2021). Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic. Human Vaccines & Immunotherapeutics, 17(11), 4126–4127. https://doi.org/10.1080/21645515.2021.1963601 Summary: The article examines the impact of the SARS-CoV-2 delta variant […]
Reference: Brosh-Nissimov, T. et al. (2021). BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2021.06.036 Summary: A study conducted in Israel examined breakthrough infections in fully-vaccinated patients who were hospitalised with COVID-19. Out of 152 patients, 40% were immunocompromised, and the study revealed that despite the
Reference: Benn, C. S., & Aaby, P. (2021). Should COVID-19 be a vaccine disease or a childhood disease? The BMJ, 374, n1687. https://doi.org/10.1136/bmj.n1687 Summary: The article discusses the implications of COVID-19 vaccination for children, highlighting concerns over the safety and necessity of such measures. It critiques the small sample size of the Pfizer phase 3
Reference: Rutenberg, D., & Zhang, Y. (2021). The clot thickens: Does the Johnson & Johnson COVID-19 vaccine increase the risk of thrombus in a hypercoagulable state? Chest, 2195. https://doi.org/10.1016/j.chest.2021.07.1937 Summary: Since January 2020, Elsevier has provided a COVID-19 resource centre offering free access to information on the novel coronavirus. The resource centre allows unrestricted sharing
Reference: Campra, P. (2021). Graphene oxide detection in aqueous suspension: Observational study in optical and electron microscopy. Interim report (I). Universidad de Almería, Spain. Summary: This interim report details the microscopic analysis of a vial labelled “COMIRNATY™,” containing a cloudy aqueous suspension. Received on 06/10/2021, the sample underwent RNA extraction and quantification, revealing the presence
Reference: Public Health England. (2021). SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 17 (25 June 2021). Retrieved from https://www.gov.uk/phe Summary: The Technical Briefing 17 from Public Health England, dated 25 June 2021, reports on the surveillance of SARS-CoV-2 variants in England. As of that date, there are four variants of
Reference: U.S. Department of Health and Human Services. (2021). Fact sheet for recipients and caregivers: Emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 12 years of age and older. Retrieved from www.cvdvaccine.com Summary: The Pfizer-BioNTech COVID-19 Vaccine is offered under emergency use authorization (EUA) to prevent
Reference: Shimabukuro, T. T., Kim, S. Y., Myers, T. R., Moro, P. L., Oduyebo, T., Panagiotakopoulos, L., Marquez, P. L., Olson, C. K., Liu, R., Chang, K. T., Ellington, S. R., Burkel, V. K., Smoots, A. N., Green, C. J., Licata, C., Zhang, B. C., Alimchandani, M., Mba-Jonas, A., Martin, S. W., Gee, J. M.,
Reference: Shimabukuro, T. T., Kim, S. Y., Myers, T. R., Moro, P. L., Oduyebo, T., Panagiotakopoulos, L., … & Meaney-Delman, D. M. (2021). Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. New England Journal of Medicine, 384(24), 2273-2282. https://doi.org/10.1056/NEJMoa2104983 Summary: The article evaluates the safety of mRNA Covid-19 vaccines in pregnant individuals, utilising
Reference: Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., Offergeld, K., Scheper, G., Taylor, K. L., Robb, M. L., Treanor, J., Barouch, D. H., Stoddard, J., Ryser, M. F., Marovich, M. A., Neuzil, K. M., Corey, L., Cauwenberghs, N., Tanner, T., Hardt,